

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Contents lists available at ScienceDirect



Autoimmunity Reviews



journal homepage: www.elsevier.com/locate/autrev

Association of COVID-19 and Acute Disseminated Encephalomyelitis (ADEM) in the absence of pulmonary involvement

Dear Editor,

The world is facing the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19, this year. COVID-19 has shown various clinical presentations ranging from fever and dyspnea to seizures and other central nervous system (CNS) manifestations [1–3].

A 30-year-old man was admitted to Sina Hospital because of ataxia and confusion.

Four weeks prior to his admission, his father was hospitalized in an intensive care unit (ICU) with COVID-19, presenting with symptoms that included fever, coughing, and dyspnea. The patient was in direct contact with his father during this time. The father was discharged with total recovery two weeks before the patient's onset of symptoms.

The patient developed ataxia and confusion two days prior to his admission to Sina Hospital. His symptoms worsened gradually, but no falling, vertigo, hearing loss, tinnitus, or visual disturbances were reported. The patient reported he could stand and walk without help and had no fever, headache, diarrhea, coughing, or dyspnea. He had not used any medication for these symptoms.

The patient's past medical and medication histories were unremarkable, and the patient had been in his usual state of good health until the initiation of symptoms.

On physical examination, the patient had right side internuclear ophthalmoparesis and ataxic gait. Confusion was noted when patient attempted to answer the physician's questions. The patient also exhibited confabulation and repeated his words several times. No fever was detected, oxygen saturation was 98% without oxygen, and all other examinations were unremarkable.

The patient's laboratory data showed white blood cells: $10.44 (*10^3/ \mu L)$ (normal range: 4–10.5), hemoglobin: 16.3 (gr/dl), CRP: 1 (mg/dl) (normal range: >6 mg/dl), and ESR: 13 (mm) (normal range: up to 18). Serum creatinine levels, sodium, potassium, TSH, and FT4 levels were within normal range as were his autoimmune panel and vasculitis tests.

Due to the COVID-19 pandemic and the positive history of the patient's father, a diagnosis of neurological manifestation of COVID-19 was initially considered. A serologic test and a nasopharyngeal and oropharyngeal swab real-time polymerase chain reaction (rt-PCR) test for SARS-CoV-2 were performed. A chest computed tomography (CT) scan showed no pathologic lesions in favor of COVID-19 (Fig. 1A). A brain magnetic resonance imaging (MRI) with and without gadolinium was also performed. The MRI showed multiple enhanced lesions suggestive of acute disseminated encephalomyelitis (ADEM) (Fig. 1 B & C). A cervical MRI without gadolinium showed a similar lesion (Fig. 1D).

Due to the patient's confusion, a lumbar puncture was performed; the results showed a clear appearance, glucose: 58 mg/dl, protein: 45.7 mg/dl, WBC: 0, and RBC: 16 (mm³) as well as positive oligoclonal bands (OCBs). Additional tests showed negative anti-aquaporin antibody and negative myelin oligodendrocyte glycoprotein antibody (MOG-IgG) results.

Rt-PCR came back negative. The serologic test showed normal IgM levels and elevated IgG levels indicating a previous infection with SARS-CoV-2.

With diagnosis of acute disseminated encephalomyelitis (ADEM) secondary to COVID-19, treatment was begun with methylprednisolone pulse therapy 1 g intravenous (IV) daily for 5 days followed by rituximab 1 g IV. After the initiation of methylprednisolone, improvement in the patient's gait and mental status was obvious. The patient was discharged with relative recovery after 7 days.

In this study, a case of ADEM secondary to COVID-19 was demonstrated. Various studies have shown the neurological manifestations of COVID-19. A retrospective case series of 214 admitted patients by Mao et al. showed prevalence rates of 8% for impaired consciousness, 3% for acute cerebrovascular problems, and 0.5% for ataxia [4,5]. Viral infections can result in ADEM, and existing evidence points out that SARS-CoV-2 is no exception [6]. One study reported a complicated case of COVID-19; the patient was initially hospitalized for coronary surgical intervention but developed complications after surgery. The chest CT scan showed pulmonary involvement typical of COVID-19, and the patient tested positive for the mentioned disease. After 2 weeks of treatment, the patient died, and autopsy revealed multiple neuropathological injuries, both vascular and demyelinating. A perivascular acute disseminated encephalomyelitis (ADEM)-like appearance was also observed in the autopsy [7].

In the beginning of the spread of SARS-CoV-2 throughout the world, it was believed that this infection is primarily targeting the pulmonary system [8]. The importance of this study is the absence of pulmonary involvement, which complicates the diagnosis of COVID-19. The only clue in the current case was the serum IgG levels that were positive for SARS-CoV-2. Due to the current pandemic, COVID-19 should be considered as a differential diagnosis for patients with neurological symptoms, especially those with rare or bizarre manifestations.

Of course it can be argued that the association of COVID-19 infection

https://doi.org/10.1016/j.autrev.2021.102753 Received 18 October 2020; Accepted 25 October 2020 Available online 18 January 2021 1568-9972/© 2021 Elsevier B.V. All rights reserved.



Fig. 1. A. Chest CT was normal. B & C. Brain MRI revealed multiple lesions with simultaneous enhancement. D. Cervical MRI revealed a plaque.

and ADEM in this case might be a coincidence, but it is important to keep in mind that a cause-and-effect relationship is also a possibility.

Referencess

- Shi Y, Wang G, Cai X-P, Deng J-W, Zheng L, Zhu H-H, et al. An overview of COVID-19. J Zhejiang Univ Sci B 2020:1.
- [2] Zhou Z, Zhao N, Shu Y, Han S, Chen B, Shu X. Effect of gastrointestinal symptoms in patients With COVID-19. Gastroenterology 2020;158(8):2294.
- [3] Abdi S, Ghorbani A, Fatehi F. The association of SARS-CoV-2 infection and acute disseminated encephalomyelitis without prominent clinical pulmonary symptoms. J Neurol Sci 2020:416.
- [4] Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: A Retrospective Case Series Study. 2020.
- [5] Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci 2020:116832.

Autoimmunity Reviews 20 (2021) 102753

- [6] Marchioni E, Tavazzi E, Minoli L, Del Bue S, Ferrante P, Piccolo G, et al. Acute disseminated encephalomyelitis. Neurol Sci 2008;29(Suppl. 2) (S286-8).
- [7] Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, Lucchinetti CF. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathol 2020:1–6.
- [8] Koralnik IJ, Tyler KL. COVID-19: a global threat to the nervous system. Ann Neurol 2020;88(1):1–11.

Shaghayegh Shahmirzaei, Abdorreza Naser Moghadasi^{*} Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran; Iran

^{*} Corresponding author at: Sina MS research Center, Sina Hospital, Tehran University of Medical Sciences, Hasan Abad Sq., Tehran, Iran. *E-mail address:* abdorrezamoghadasi@gmail.com (A. Naser Moghadasi).